Efficacy and Harms of Direct Oral Anticoagulants in the Elderly for Stroke Prevention in Atrial Fibrillation and Secondary Prevention of Venous Thromboembolism: Systematic Review and Meta-Analysis

Running title: Sharma et al.; Use of direct oral anticoagulants in the elderly

Manuj Sharma, M Clin Res1,2; Victoria R. Cornelius, PhD1; Jignesh P. Patel, PhD3,4;

J. Graham Davies, PhD4; Mariam Molokhia, PhD1

1Dept of Primary Care and Public Health Sciences, King’s College London, London; 2Dept of Clinical Pharmacy, Guy’s and St Thomas Hospital NHS Foundation Trust, London; 3Dept of Haematological Medicine, King’s College Hospital, London; 4Institute of Pharmaceutical Science, King’s College London, London, United Kingdom

Address for Correspondence:
Manuj Sharma, M Clin Res
Dept of Primary Care & Public Health Sci
King’s College London
Capital House, Weston Street
London SE1 3QD
United Kingdom
Tel: 00447508370240
Fax: 00442032994689
E-mail: manujsharma2014@gmail.com

Mariam Molokhia, PhD
Dept of Primary Care & Public Health Sci
King’s College London
Capital House, Weston Street
London SE1 3QD
United Kingdom
Tel: 00447508370240
Fax: 00442032994689
E-mail: mariam.molokhia@kcl.ac.uk

Abstract

**Background**—Evidence regarding use of direct oral anticoagulants (DOACs) in the elderly, particularly bleeding risks, is unclear despite the presence of greater comorbidities, polypharmacy and altered pharmacokinetics in this age group.

**Methods and Results**—We performed a systematic review and meta-analysis of randomised trials of DOACs (dabigatran, apixaban, rivaroxaban, edoxaban) for efficacy and bleeding outcomes compared to VKA (vitamin k antagonists) in elderly participants (aged ≥75 years) treated for acute venous thromboembolism or stroke prevention in atrial fibrillation. Nineteen studies were eligible for inclusion but only 11 reported data specifically for elderly participants. Efficacy in managing thrombotic risks for each DOAC was similar or superior to VKA in the elderly. A non-significantly, higher risk of major bleeding than VKA was observed with dabigatran 150mg (Odds Ratio 1.18, 95% confidence interval 0.97-1.44) but not with the 110mg dose. Significantly higher gastrointestinal bleeding risks with dabigatran 150mg (1.78, 1.35-2.35) and 110mg (1.40, 1.04-1.90) and lower intracranial bleeding risks than VKA for 150mg (0.43, 0.26-0.72) and 110mg (0.36, 0.22-0.61) were also observed. A significantly lower major bleeding risk compared to VKA was observed for apixaban (0.63, 0.51-0.77), edoxaban 60mg (0.81, 0.67-0.98) and 30mg (0.46, 0.38-0.57) while rivaroxaban showed similar risk.

**Conclusions**—DOACs demonstrated at least equal efficacy to VKA in managing thrombotic risks in the elderly however bleeding patterns were distinct. In particular, dabigatran was associated with a higher risk of gastrointestinal bleeding than VKA. Insufficient published data for apixaban, edoxaban and rivaroxaban indicates further work is needed to clarify their bleeding risks in the elderly.

**Key words:** elderly, anticoagulant, bleeding, atrial fibrillation, venous thromboembolism
Introduction

Advanced age is a significant risk factor for atrial fibrillation (AF) and venous thromboembolism (VTE). AF prevalence estimates are <0.1% in the population aged <55 years and rise to over 8% in those aged >80 years. Patients with AF have a five-fold greater risk of stroke. The increased risk of VTE with age is also estimated to double with every decade after the age of 40. The major complication of VTE is recurrence. Anticoagulant therapy is essential for managing these thrombotic risks, particularly in an ageing population who are at higher risk.

Vitamin K antagonists (VKA) have until recently been the only oral anticoagulant treatment option available for patients. However four direct oral anticoagulants (DOACs), dabigatran, rivaroxaban, apixaban and edoxaban have now undergone trials to investigate their harm for use and efficacy in the management of thromboembolic risk in AF and acute VTE. They have been adopted into clinical practice as they confer certain practical advantages over VKA. They are reported to have less drug-drug and drug-food interactions and have been licensed for use without the need for routine monitoring of anticoagulation effect. This is due to their predictable pharmacokinetic profiles. However, as for VKA, they pose a significant risk of bleeding which is complicated further by the lack of a reversal agent.

Though several reviews have evaluated the efficacy and harms of DOACs in the general population, the specific evidence base for their use in the elderly aged ≥75 years remains unclear. The risk of harm with DOACs compared to VKA, in particular bleeding risks, warrants clarity given the presence of greater comorbidities, polypharmacy and altered pharmacokinetics in the elderly.

We undertook a systematic review and meta-analysis of randomised controlled trials for use of the DOACs in the management of AF and acute VTE, where VKA were used as a
comparator. No randomised controlled trial for DOACs has been conducted thus far that involves only elderly participants. Hence, our approach was to evaluate the DOACs for efficacy and harms compared to VKA in the elderly participants aged ≥75 years from each trial. These results were then put in context by presenting the results from the total trial populations (all ages), based on which marketing authorisations for DOACs have been granted.

Methods

Eligibility Criteria

We identified all phase II and III randomised controlled trials of the DOACs (dabigatran 150mg and 110mg, apixaban, rivaroxaban and edoxaban 60mg and 30mg) in patients being treated for acute VTE (deep vein-thrombosis and/or pulmonary embolism) and for stroke prevention in AF. We required that studies have a minimum of 3 months patient follow-up and used VKA as a comparator. For phase II studies, we extracted data for doses that were used for subsequent phase III clinical trials only. We excluded studies if they were extensions of previously completed trials for additional follow-up.

Search Strategy

Medline, Embase and CENTRAL (Cochrane central register of controlled trials) were searched for articles in English from 22nd November 1993 to 22nd November 2013. The search was subsequently updated to June 1st 2014. Search strategies for each database are presented in the Supplementary Material. Clinical trial registries were also searched and conference proceedings were identified using web of science, scopus and international pharmacy abstracts. Additional studies, including unpublished and grey literature were identified by screening reference lists of retrieved studies and review articles. In instances where subgroup data for elderly patients aged
≥75 years was unpublished, drug manufacturers, authors and relevant regulatory bodies e.g. US FDA (United States Food and Drug safety Administration) and EMA (European Medicines Agency) were contacted to request the data. The search strategy was checked for appropriateness by a second investigator.

**Study Selection**

One reviewer (MS) performed the full search strategy, removed duplicates and selected the articles. One of three other independent reviewers (VC, JP, JGD) analysed these selections for eligibility of inclusion. Studies were screened based on title and abstract initially, following which full texts were obtained and assessed for inclusion.

**Data Extraction**

All data was extracted by two reviewers (MS with VC, JP or JGD) independently into standardised forms and entered into Microsoft Excel®. Data extracted included study details, participant details, intervention details (drug name, dose, frequency) and comparator details (time in therapeutic range). Data was collected for the subgroup of elderly patients aged ≥75 years and the total trial population (all ages) for each study. The intention to treat populations were used where possible. Primary efficacy outcomes were stroke or systemic embolism for AF trials, and recurrent venous thromboembolism for VTE studies. The primary safety outcome was pooled major bleeding from both AF and VTE studies. Secondary outcomes were gastrointestinal bleeding, intracranial bleeding, clinically relevant bleeding and fatal bleeding. Studies were also assessed for potential bias (low, unclear, high) using the Cochrane Collaboration’s risk of bias assessment. All disagreements between reviewers were resolved by consensus or discussion with a third reviewer.
Statistical Analyses

The treatment effect for DOAC compared to VKA was estimated by meta-analyses for each drug separately (dabigatran 150mg and 110mg, apixaban, rivaroxaban and edoxaban 60mg and 30mg). This was undertaken for elderly participants aged ≥75 years for each outcome of interest. It was then repeated for the total trial participants to allow comparison. Data synthesis was invariably undertaken using a Peto Odds ratio fixed effect model. However, when there was high heterogeneity with greater than 4 studies contributing to the estimate; a random effects model (DerSimonian and Laird) was used. Use of a random effects model to determine estimates is highlighted in the results through use of the annotation “Random Effects” in brackets alongside the odds ratio estimate. Study heterogeneity was analysed using the I-squared statistic. Sensitivity analysis was undertaken by indication, mean duration of patient follow up (<6months vs ≥6months) and where high heterogeneity (>75%) was evident. A funnel plot was used to assess publication bias. The manuscript was prepared in accordance with the preferred reporting items for systematic reviews and meta-analysis (PRISMA). All analyses were performed using Review Manager® software (Rev Man 5.2®). Where only confidence intervals were available for outcomes, event rates were calculated using the method detailed by Tierney and colleagues.

Results

Our search identified 19 multi-centred, randomised controlled trials eligible for inclusion with 11 reporting data on elderly patients as shown in Supplemental Figure 1. Detailed rationale behind exclusion of studies is presented in Supplemental Table S1. Additional unpublished data was requested for all 19 studies from manufacturers, authors and regulatory authorities but only data for 4/19 (21.0%) studies was obtained. Additional data from documentation published by
regulatory authorities and conference proceedings for 6/19 (31.6%) studies was also retrieved.19,20,23-26

**Study Characteristics**

Eleven phase III and 8 phase II studies consisting of 5 dabigatran trials,24,27-30 4 apixaban trials,26,31-33 5 rivaroxaban trials,19-23 and 5 edoxaban trials.25,34-37 All studies used warfarin as comparator with 4 studies also allowing use of other VKAs.19,20,23,33 Follow-up periods were longest for the phase III AF studies as shown in Table 1. Included studies mostly used definitions for major bleeding as per International Society of Thrombosis and Haemostasis,38 while two phase II studies used a slight variation of this definition.25,36 Definitions used to classify clinically relevant bleeding showed minimal variation and essentially consisted of a major bleed or any overt bleeding event that did not meet the criteria for major bleeding but led to either hospital admission for bleeding, physician-guided treatment or an alteration in therapy. Intracranial and fatal bleeding were both included as part of the major bleeding events. Gastrointestinal bleeding was recorded also as either a major or clinically relevant bleed based on independent adjudication in each study.

**Patient Characteristics**

Data was reported for 31,418 elderly participants aged ≥75 years out of a total of 102,479 participants aged ≥18 years. Mean age ranged from 64.5 to 71.7 years in AF studies and 54.4 to 59.0 years in VTE studies (Table 2). Mean CHADS2 for AF studies ranged from 1.8 to 3.5 where reported while percentage of patients recruited with a history of a previous VTE ranged from 15.8% to 29.0% in the VTE studies. The Rocket-AF study recruited patients with the highest CHADS2 scores of 3.5 in each arm.22 The dabigatran study, Recover I, was the phase III study that recruited the highest percentage of patients with previous VTE for DOAC (25.7%) and
VKA (25.4%) therapy respectively. All studies permitted usage of aspirin if necessary with DOAC, however the percentage of patients on aspirin in individual studies was inadequately reported as shown in Supplemental Table S2.

Risk of Bias Assessment

Results of the risk of bias assessment for all 19 studies are presented in Figure 1. Eleven studies were open-label and at high risk of bias from lack of blinding of patients and personnel to the intervention. However, all studies where reported were assessed by blinded adjudicators for the outcomes. Two studies were deemed to be at high risk of bias from incomplete outcome data due to unclear attrition. In both Rocket-AF and Einstein-DVT dose, 93 patients were omitted from analysis due to protocol violations. Bibr 1048 was judged to be at risk of other bias because a full publication for the trial was not available. The funnel plots as shown in Figure 2 for the total population indicate we obtained a reasonable expected balance of positive and negative results from the included studies. Only 11 studies reported data on the elderly population hence assessment of publication bias was challenging. Data was requested from the pharmaceutical companies and regulatory bodies where elderly subgroup data had not been reported. However, only limited data was made available.

Outcomes

Primary Efficacy Outcomes

Each DOAC was shown to be at least as effective as VKA in the elderly. This was both in reducing risk of stroke or systemic embolism in AF, and risk of recurrent venous thromboembolism in VTE. Efficacy observed was also similar to that seen in the total population (all ages).

In AF studies, a significant reduction in risk of stroke or systemic embolism compared to
VKA was observed for dabigatran 150mg (Odds Ratio 0.66, 95% confidence interval 0.49-0.90; p=0.009) and apixaban (OR 0.70, 95% CI 0.52-0.93; p=0.01). This significant risk reduction was also maintained in the total populations for both DOACs (Figure 3).

Results in the elderly for all four DOACs in reducing risk of recurrent VTE are shown in Figure 4. These estimates were limited by low event rates but did not indicate inferiority compared to VKA. Results from the total population also supported non-inferiority to VKA.

Primary Safety Outcome

Major bleeding

In the elderly, a significant reduction in risk of major bleeding compared to VKA was observed for apixaban (OR 0.63, 95% CI 0.51-0.77; p<0.0001), edoxaban 60mg (OR 0.81, 95% CI 0.67-0.98; p=0.03) and 30mg (OR 0.46, 95% CI 0.38-0.57; p<0.0001). The superiority to VKA for these DOACs was also observed in the total population (Figure 5).

Dabigatran 150mg showed a non-significant, higher risk of major bleeding compared to VKA in the elderly (OR 1.18, 95% CI 0.97-1.44; p=0.10); though risk was similar to VKA with the 110mg dose. In contrast in the total population, a non-significant lower risk than VKA was observed with the 150mg dose; while a significantly lower risk was observed with the 110mg dose.

Secondary Outcomes

Gastrointestinal bleeding

In the elderly, gastrointestinal bleeding was significantly increased compared to VKA with dabigatran 150mg (OR 1.78, 95% CI 1.35-2.35; p<0.0001) and 110mg (OR 1.40, 95% CI 1.04-1.90; p=0.03) (Figure 6). Data regarding risk of gastrointestinal bleeding in the elderly for the other DOACs was not published or made available.
For the total population: the significantly increased risk of gastrointestinal bleeding compared to VKA was sustained with dabigatran 150mg, but not with the 110mg dose. In the total population, rivaroxaban and edoxaban 60mg also showed a significantly higher risk of gastrointestinal bleeding than VKA.

**Intracranial bleeding**

In the elderly, a significant reduction in risk of intracranial bleeding compared to VKA was observed for dabigatran 150mg (OR 0.43, 95% CI 0.26-0.72; p=0.001) dabigatran 110mg (OR 0.36, 95% CI 0.22-0.61; P=0.0001) and apixaban (OR 0.38, 95% CI 0.24-0.59; p<0.0001). A non-significant reduction was also observed for rivaroxaban while data was not available for edoxaban in the elderly.

In the total population all DOACS showed a significantly lower risk of intracranial bleeding compared to VKA as shown in Figure 6.

**Clinically Relevant Bleeding**

In the elderly, the risk of clinically relevant bleeding where reported was not significantly different for DOACs compared to VKA; except for apixaban, which demonstrated superiority to VKA; (OR 0.64, 95% CI 0.54-0.76; p<0.0001; Random Effects).

In the total population, apixaban, dabigatran 150mg and edoxaban 60mg and 30mg demonstrated superiority to VKA in reducing this risk (Figure 6).

**Fatal Bleeding**

In the elderly, the risk of fatal bleeding where reported was not significantly different for DOACs to VKA; except for rivaroxaban which showed superiority (OR 0.53, 95% CI 0.30-0.93; p=0.03). Data for this outcome was limited by the low number of fatal bleeding events in the studies. No data was available for edoxaban.
In the total population, a significantly reduced risk of fatal bleeding compared to VKA was observed for dabigatran 110mg, rivaroxaban, edoxaban 60mg, and edoxaban 30mg (Figure 6).

**Heterogeneity Assessment and Sensitivity Analysis**

Significant heterogeneity ($I^2>$75%) was found when all four DOACs were pooled together and compared to VKA for major bleeding, gastrointestinal bleeding and fatal bleeding. Moderate heterogeneity ($I^2=$50-75%) was found for risk of stroke or systemic embolism and intracranial bleeding. Sensitivity analysis undertaken by removing the only direct thrombin inhibitor, dabigatran, and leaving in the three factor Xa inhibitors showed similar high heterogeneity across outcomes. Investigation indicated that this high heterogeneity may be due to either differing baseline bleeding risks in the studies or true differences between each DOAC which, when pooled, were masked. This is why results for all four DOACs pooled together compared to VKA are not presented.

There was evidence of statistical heterogeneity in the estimate for risk of major bleeding compared to VKA for rivaroxaban in the elderly ($I^2=82\%$). This was largely attributable to the unusually high number of bleeding events in the VKA arm in Einstein PE compared to the other three rivaroxaban AF and VTE studies. Heterogeneity was also present for the estimate for risk of clinically relevant bleeding for apixaban in the total population ($I^2=81\%$). Sensitivity analysis did not yield a satisfactory source for this heterogeneity. Hence, a random effects model was applied.16 No other outcome estimate produced significant heterogeneity.

Additional sensitivity analysis by indication and mean duration of patient follow up did not significantly alter interpretation of findings in the elderly except in the case of rivaroxaban for major bleeding. For rivaroxaban, in AF the major bleeding risk was (OR 1.17, 95%CI 0.95-1.43) and in VTE it was (OR 0.30, 95%CI 0.15-0.58).
Discussion

This systematic review and meta-analysis investigating use of DOACs in AF and VTE has shown that they are at least as effective as VKA in the elderly aged ≥75 years. Similar efficacy was also seen in the elderly and total trial populations (all ages). The meta-analysis of bleeding risks with DOACs has shown them to be distinct to VKA. For the direct thrombin inhibitor, dabigatran, risks also appeared to differ for bleeding between elderly and total trial populations. Dabigatran 150mg showed a non-significantly higher risk of major bleeding than VKA in the elderly. However, in the total population a reduction in major bleeding was observed with dabigatran compared to VKA which was significant for the 110mg dose. Two of the direct factor Xa inhibitors (apixaban and edoxaban) showed a lower major bleeding risk to VKA in both the elderly and total population; while rivaroxaban showed a similar risk.

Elderly patients taking either dose of dabigatran were at higher risk of gastrointestinal bleeding than those on VKA; this risk was also present in the total populations but with the 150mg dose only. Use of DOACs provided a protective effect compared to VKA against intracranial bleeding in the elderly that was consistent with the total population. Results where available for clinically relevant bleeding, or fatal bleeding for DOACs did not suggest different risks to VKA in the elderly. However, interpretation of these secondary bleeding outcomes in the elderly was limited by the low numbers of elderly patients with bleeding events in the studies.

This was compounded by the fact that all data requested from pharmaceutical manufacturers and regulatory authorities we approached was not made available.

The intention from our protocol was to provide pooled outcome data for all four DOACs together versus VKA as well. However, we found significant heterogeneity when the drugs were combined for several outcomes. This appeared to be due to either differing baseline bleeding...
risks in the studies or true differences between each drug. Hence, this result was not deemed appropriate to present.

Our choice of the total trial population as our reference group for contextualising the results in the elderly was based on guidance in the Cochrane handbook on conducting subgroup meta-analysis in trials. Comparing two subgroup meta-analyses, ages ≥75 to <75 for example, based purely on statistical significance of subgroup results would have been misleading as both analyses are likely to have different abilities to detect effects. Hence, we did not choose the <75 population as our main reference though we have included the meta-analysis for the <75 population in the supplementary appendix online.

The sub-group analysis of the dabigatran Phase III, Re-ly trial suggested that major bleeding risk may increase with age for dabigatran. Our study has suggested, however that this risk increase is not significantly greater than VKA. Dabigatran relies more on renal excretion for elimination than the other three DOACs. Given that renal function declines with age, this may be a factor for greater bleeding risk. However, renal function alone cannot fully explain this variation in bleeding risk which is likely to be influenced by other unverified age-related factors as well.

The increased risk of gastrointestinal bleeding and associated mortality with age has been well established. Use of anticoagulant medication is known to increase this risk further. Gastrointestinal bleeding was found to significantly increase with rivaroxaban, edoxaban 60mg and dabigatran 150mg compared to VKA in the total population. This risk increased further for dabigatran in the elderly. Gastrointestinal bleeding risks with other DOACs in the elderly could not be examined due to the lack of availability of data. This was a serious concern given that gastrointestinal bleeding has been shown both in this study and previous work to be a significant
risk with usage of DOACs.

Use of VKA and advanced age are both strong predictive factors for intracranial bleeding. The protective benefit against intracranial bleeding that the DOACs confer over VKA in the general population did not appear to be lost in the elderly. Given that intracranial bleeding is one of the major factors responsible for mortality resulting from complications of VKA usage, this finding was significant.43

It is worth noting that the pooled bleeding results in this study are heavily weighted towards the large pivotal phase III AF study for each of the four DOACs.22, 26, 27, 35 As a result, the respective trial populations in these studies should be considered. Notably, the population in the edoxaban (Engage-AF-Timi48),35 and rivaroxaban study (Rocket-AF),22 both had higher mean CHADS2 risk scores of 2.8 and 3.5 respectively compared to 2.1 in both the dabigatran (Re-ly)27 and apixaban (Aristotle)26 studies. The CHADS2 risk assessment tool can help predict risk of stroke in patients with AF,44 and indicated inclusion of a lower risk population in Re-ly and Aristotle. Mean time in therapeutic range (TTR) on VKA did vary across the four studies (55.0%-64.9%); and Rocket-AF was lowest with 55%. Such deviations in TTR are, however also common in clinical practice.45 These differences in the trial populations mean comparisons between DOACs can be misleading and were not undertaken here. Until head to head clinical trials comparing the DOACs against one another are conducted, it will not be possible to know which DOAC has the best efficacy and harm profile in the elderly or total populations.

Research in Context

This is the first study that has attained and assessed all available evidence for dabigatran, apixaban, rivaroxaban and edoxaban in AF and VTE treatment in the elderly from literature, regulatory bodies and drug manufacturers. The DOACs have been tested for other indications
such as thromboprophylaxis following hip and knee replacements. However, these studies used different doses and comparators and hence were not eligible for inclusion.46

“Real world” data is gradually emerging for the DOACs though such observational data can be subject to confounding.47-49 Studies investigating the risks of dabigatran thus far have produced conflicting results.48,49 A Danish cohort study for example, found significantly worse bleeding patterns with dabigatran 110mg in the total population than seen in this analysis.49 Two small studies also highlighted how bleeding risks in particular in the elderly remain a significant concern with dabigatran.50,51 As further information emerges from larger studies such as the prospective DOAC register in Dresden, harms and benefits for DOACs in the elderly will become clearer.52

Limitations of this study

Interpretation of subgroup data from clinical trials for elderly patients aged ≥75 years requires caution as trials were not initially powered to detect these differences. Randomisation in studies was not stratified by age; hence it was not possible to ensure all confounders such as concomitant aspirin usage or impaired renal function were balanced across arms. Population sizes for primary outcomes, however were reasonably large. Our data was also limited by lack of published results in the public domain or available from regulatory authorities and manufacturers. This meant that several summary estimates in the elderly were based on only one or two studies. Due to the lack of patient level data, we were unable to ascertain the age distribution of our elderly participants and number of ‘frail’ elderly patients aged above 80 and 85 years that had actually been included.

Outcome data on cardiovascular events was not reported. A signal for increased risk of myocardial infarction with dabigatran compared to VKA has been previously raised.53 However,
a large post-marketing surveillance study completed by the FDA has not found this risk to be significant.54

In the VTE studies, it was common for patients to receive several days (median 2-9 days) of a heparin before beginning treatment with either a DOAC or VKA.28, 29, 34 In Amplify, Einstein- DVT and Einstein-PE they received a higher dose of oral anticoagulant for a short period prior to initiation of standard DOAC dose.19, 20, 31 Also, as bleeding definitions were not mutually exclusive within trials; some estimates of risk by bleeding classification were difficult to interpret. These factors could ultimately affect the precision of bleeding estimates. Follow-up did vary between studies, however all had at least 3 months and covered the initial period during which harm has been found to be highest with usage of anticoagulants.55

Conclusion

DOAC’s showed at least equal efficacy to VKA in the elderly for acute VTE and AF. However, bleeding patterns seen with DOACs were different. Dabigatran, in particular, showed a significantly higher risk of gastrointestinal bleeding and a non-significantly higher major bleeding risk than VKA. This suggests that caution is required in prescribing where there may be concomitant risk factors for gastrointestinal bleeding in the elderly. A benefit of reduced intracranial bleeding was seen with dabigatran, apixaban and rivaroxaban. Insufficient published data for apixaban, edoxaban and rivaroxaban meant all bleeding risks, particularly gastrointestinal risks, could not be fully explored in the elderly. Better availability of unpublished trial data and more research is needed to elucidate risks further.
Funding Sources: This research was supported by the National Institute for Health Research (NIHR) Biomedical Research Centre at Guy's and St Thomas' NHS Foundation Trust and King's College London. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.

Conflict of Interest Disclosures: MS, VC and JGD have no competing interests to declare. JP has received research funding through an investigator-initiated grant from Bayer. MM has received previous grants from AstraZeneca, Pfizer and the Serious Adverse Events Consortium for drug safety studies unrelated to this work.

References:


42. Yachimski PS, Friedman LS. Gastrointestinal bleeding in the elderly. *Nat Clin Pract*


Table 1. Characteristics of included studies for DOACs in atrial fibrillation and venous thromboembolism.

<table>
<thead>
<tr>
<th>Study</th>
<th>Indication</th>
<th>Standard Dose</th>
<th>Phase</th>
<th>Duration/Median Follow up* (months)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>DABIGATRAN</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bibr 1048, 2005^24</td>
<td>AF</td>
<td>110mg BD or 150mg BD</td>
<td>II</td>
<td>3</td>
</tr>
<tr>
<td>Petro, 2007^30</td>
<td>AF</td>
<td>150mg BD extracted</td>
<td>II</td>
<td>3</td>
</tr>
<tr>
<td>Re-ly, 2009^27</td>
<td>AF</td>
<td>110mg or 150mg BD</td>
<td>III</td>
<td>24*</td>
</tr>
<tr>
<td>Recover I, 2010^28</td>
<td>VTE</td>
<td>150mg BD</td>
<td>III</td>
<td>6</td>
</tr>
<tr>
<td>Recover II, 2013^29</td>
<td>VTE</td>
<td>150mg BD</td>
<td>III</td>
<td>6</td>
</tr>
<tr>
<td><strong>APIXABAN</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aristotle, 2011^26</td>
<td>AF</td>
<td>5mg BD</td>
<td>III</td>
<td>21.6*</td>
</tr>
<tr>
<td>Aristotle-J, 2011^32</td>
<td>AF</td>
<td>5mg BD extracted</td>
<td>II</td>
<td>3</td>
</tr>
<tr>
<td>Botticelli-DVT, 2008^33</td>
<td>VTE</td>
<td>5mg BD</td>
<td>II</td>
<td>3</td>
</tr>
<tr>
<td>Amplify, 2013^31</td>
<td>VTE</td>
<td>10mg BD for 7 days then 5mg BD</td>
<td>III</td>
<td>6</td>
</tr>
<tr>
<td><strong>RIVAROXABAN</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rocket-AF, 2011^22</td>
<td>AF</td>
<td>20mg OD</td>
<td>III</td>
<td>23.2*</td>
</tr>
<tr>
<td>J-Rocket AF, 2011^21</td>
<td>AF</td>
<td>15mg OD</td>
<td>III</td>
<td>30</td>
</tr>
<tr>
<td>Einstein-DVT Dose Study, 2008^23</td>
<td>VTE</td>
<td>20mg OD extracted</td>
<td>II</td>
<td>3</td>
</tr>
<tr>
<td>Einstein-DVT, 2010^19</td>
<td>VTE</td>
<td>15mg BD for 21 days then 20mg OD</td>
<td>III</td>
<td>3, 6 or 12</td>
</tr>
<tr>
<td>Einstein-PE, 2012^20</td>
<td>VTE</td>
<td>15mg BD for 21 days then 20mg OD</td>
<td>III</td>
<td>3, 6 or 12</td>
</tr>
<tr>
<td><strong>EDOXABAN</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Edox-P2, 2010^36</td>
<td>AF</td>
<td>30mg or 60mg OD extracted</td>
<td>II</td>
<td>3</td>
</tr>
<tr>
<td>Edox-P2A, 2010^25</td>
<td>AF</td>
<td>30mg OD or 60mg OD</td>
<td>II</td>
<td>3</td>
</tr>
<tr>
<td>Edox-J, 2012^37</td>
<td>AF</td>
<td>30mg or 60mg OD</td>
<td>II</td>
<td>3</td>
</tr>
<tr>
<td>Engage-AF-Timi 48, 2013^38</td>
<td>AF</td>
<td>30mg OD or 60mg OD</td>
<td>III</td>
<td>33.6*</td>
</tr>
<tr>
<td>Hokusai-VTE, 2013^34</td>
<td>VTE</td>
<td>60mg OD</td>
<td>III</td>
<td>3 to 12</td>
</tr>
</tbody>
</table>

OD= Once daily; BD=Twice daily
Table 2. Patient Characteristics in included studies for DOACs in atrial fibrillation and venous thromboembolism.

<table>
<thead>
<tr>
<th>Study</th>
<th>Total Participants</th>
<th>Participants ≥75</th>
<th>Mean Age (SD)</th>
<th>Men%</th>
<th>CHADS2 (SD)</th>
<th>Previous VTE (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>DOAC</td>
<td>VKA</td>
<td>DOAC</td>
<td>VKA</td>
<td>DOAC</td>
<td>VKA</td>
</tr>
<tr>
<td>DABIGATRAN</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bibr 1048, 2005&lt;sup&gt;24&lt;/sup&gt;</td>
<td>104</td>
<td>62</td>
<td>NA</td>
<td>NA</td>
<td>69.0 (8.4)</td>
<td>67.4 (8.8)</td>
</tr>
<tr>
<td>Petro, 2007&lt;sup&gt;20&lt;/sup&gt;</td>
<td>169</td>
<td>70</td>
<td>NA</td>
<td>NA</td>
<td>70.0 (8.1)</td>
<td>69.0 (8.3)</td>
</tr>
<tr>
<td>Re-ly, 2009&lt;sup&gt;27&lt;/sup&gt;</td>
<td>12091</td>
<td>6022</td>
<td>4815</td>
<td>2423</td>
<td>71.4 (8.7)</td>
<td>71.6 (8.6)</td>
</tr>
<tr>
<td>Recover I, 2010&lt;sup&gt;28&lt;/sup&gt;</td>
<td>1274</td>
<td>1265</td>
<td>NA</td>
<td>NA</td>
<td>55.0 (15.8)</td>
<td>54.4 (16.2)</td>
</tr>
<tr>
<td>Recover II, 2013&lt;sup&gt;29&lt;/sup&gt;</td>
<td>1279</td>
<td>1289</td>
<td>NA</td>
<td>NA</td>
<td>54.7 (16.2)</td>
<td>55.1 (16.3)</td>
</tr>
<tr>
<td>APIXABAN</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aristotle, 2011&lt;sup&gt;26&lt;/sup&gt;</td>
<td>9120</td>
<td>9081</td>
<td>2850</td>
<td>2828</td>
<td>69.1 (9.6)</td>
<td>69.0 (9.7)</td>
</tr>
<tr>
<td>Aristotle-J, 2011&lt;sup&gt;32&lt;/sup&gt;</td>
<td>74</td>
<td>74</td>
<td>45</td>
<td>23</td>
<td>70.0 (8.1)</td>
<td>71.7 (7.0)</td>
</tr>
<tr>
<td>Botticelli-DVT, 2008&lt;sup&gt;33&lt;/sup&gt;</td>
<td>130</td>
<td>128</td>
<td>NA</td>
<td>NA</td>
<td>56.0 (14.0)</td>
<td>59.0 (16.0)</td>
</tr>
<tr>
<td>Amplify, 2013&lt;sup&gt;31&lt;/sup&gt;</td>
<td>2691</td>
<td>2704</td>
<td>398</td>
<td>370</td>
<td>57.2 (16.0)</td>
<td>56.7 (16.0)</td>
</tr>
<tr>
<td>RIVAROXABAN</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rocket-AF, 2011&lt;sup&gt;22&lt;/sup&gt;</td>
<td>7131</td>
<td>7133</td>
<td>3082</td>
<td>3082</td>
<td>71.2 (9.4)</td>
<td>71.2 (9.4)</td>
</tr>
<tr>
<td>J-Rocket AF, 2011&lt;sup&gt;21&lt;/sup&gt;</td>
<td>640</td>
<td>649</td>
<td>252</td>
<td>246</td>
<td>71.0 (8.3)</td>
<td>71.2 (7.9)</td>
</tr>
<tr>
<td>Einstein-DVT Dose Study, 2008&lt;sup&gt;23&lt;/sup&gt;</td>
<td>136</td>
<td>137</td>
<td>NA</td>
<td>NA</td>
<td>58.0</td>
<td>57.0</td>
</tr>
<tr>
<td>Einstein-DVT, 2010&lt;sup&gt;19&lt;/sup&gt;</td>
<td>1731</td>
<td>1718</td>
<td>215</td>
<td>225</td>
<td>55.8 (16.4)</td>
<td>56.4 (16.3)</td>
</tr>
<tr>
<td>Einstein-PE, 2012&lt;sup&gt;20&lt;/sup&gt;</td>
<td>2419</td>
<td>2413</td>
<td>441</td>
<td>402</td>
<td>57.9 (7.3)</td>
<td>57.5 (7.2)</td>
</tr>
<tr>
<td>EDOXABAN</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Edox-P2, 2010&lt;sup&gt;16&lt;/sup&gt;</td>
<td>470</td>
<td>251</td>
<td>NA</td>
<td>NA</td>
<td>65.0 (8.6)</td>
<td>66.0 (8.5)</td>
</tr>
<tr>
<td>Edox-P2A, 2010&lt;sup&gt;25&lt;/sup&gt;</td>
<td>159</td>
<td>76</td>
<td>21</td>
<td>10</td>
<td>65.4 (8.4)</td>
<td>64.5 (9.5)</td>
</tr>
<tr>
<td>Edox-J, 2012&lt;sup&gt;37&lt;/sup&gt;</td>
<td>267</td>
<td>134</td>
<td>77</td>
<td>35</td>
<td>68.9</td>
<td>68.8</td>
</tr>
<tr>
<td>Engage-AF-Timi 48, 2013&lt;sup&gt;35&lt;/sup&gt;</td>
<td>14069</td>
<td>7036</td>
<td>5654</td>
<td>2820</td>
<td>70.6(9.4)</td>
<td>70.5(9.4)</td>
</tr>
<tr>
<td>Hokusai-VTE, 2013&lt;sup&gt;34&lt;/sup&gt;</td>
<td>4143</td>
<td>4149</td>
<td>560</td>
<td>544</td>
<td>55.7 (16.3)</td>
<td>55.9 (16.2)</td>
</tr>
</tbody>
</table>

NA= Not available; SD= Standard Deviation
Figure Legends:

Figure 1. Summary of risk of bias assessment. Green(+) = Low bias risk; Red (-) = High bias risk; Yellow(?) = Unclear bias risk.

Figure 2. Funnel Plot comparison for risk of major bleeding in the elderly and total population. *Note: Y axis scales differ between plots.

Figure 3. Risk of stroke or systemic embolism in atrial fibrillation studies in elderly and total population. *Event numbers for Engage-AF-Timi 48 in elderly have been estimated from published confidence intervals.

Figure 4. Risk of recurrent venous thromboembolism in venous thromboembolism studies in elderly and total population.

Figure 5. Risk of major bleeding in elderly and total population. *Event numbers for Engage-AF-Timi-48 and J-Rocket AF in the elderly have been estimated from published confidence intervals.

Figure 6. Risk of secondary outcomes in elderly and total population. GIB = Gastrointestinal bleeding; ICB = Intracranial Bleeding; CRB = Clinically Relevant Bleeding; FB = Fatal Bleeding. *CRB estimate was only estimate derived using a random effects model. **Note: Full Forest Plots for each estimate above are available in the supplementary appendix online.
| Figure 1 | Rocket-AF | Re-ly | Recover II | Recover I | Petro | J-Rocket AF | Hokusai-VTE | EHE-Engage-AF-Timi 48 | EHE-Einstein-DVT dose study | EHE-Einstein-DVT | EDOX-P2A | EDOX-J | Botecel-DVT | Bbr 1048 | Aristotle-J | Aristotle | Amplify |
|----------|-----------|-------|------------|-----------|-------|-------------|-------------|------------------------|------------------------|----------------|---------|---------|-----------|---------|-------------|-----------|
| Random sequence generation (selection bias) | + | + | + | + | 2 | ? | + | + | + | + | + | 2 | ? | + | + | + |
| Allocation concealment (selection bias) | + | + | + | + | 2 | ? | + | + | + | + | + | 2 | ? | + | + | + |
| Blinding of participants and personnel (performance bias) | + | 1 | + | + | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Blinding of outcome assessment (detection bias) | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + |
| Incomplete outcome data (attrition bias) | + | 2 | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + |
| Selective reporting (reporting bias) | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + |
| Other bias | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + |
Figure 2

Funnel Plot for risk of major bleeding in the total population

Subgroups:
- Dabigatran 150mg vs VKA
- Dabigatran 110mg vs VKA
- Rivaroxaban vs VKA
- Apixaban vs VKA
- Edoxaban 60mg vs VKA
- Edoxaban 30mg vs VKA
Elderly Population aged 75

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>DOAC Events Total</th>
<th>VKA Events Total</th>
<th>Peto Odds Ratio Peto, Fixed, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1.1 Dabigatran 150mg vs VKA</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Re-ly</td>
<td>69 2466</td>
<td>101 2423</td>
<td>0.66 [0.49, 0.90]</td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>2466</td>
<td>2423</td>
<td>0.66 [0.49, 0.90]</td>
</tr>
<tr>
<td><strong>1.2 Dabigatran 110mg vs VKA</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Re-ly</td>
<td>87 2349</td>
<td>101 2423</td>
<td>0.88 [0.66, 1.18]</td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>2349</td>
<td>2423</td>
<td>0.88 [0.66, 1.18]</td>
</tr>
<tr>
<td><strong>1.3 Rivaroxaban vs VKA</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rocket-AF</td>
<td>125 3082</td>
<td>154 3082</td>
<td>0.80 [0.63, 1.02]</td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>3082</td>
<td>3082</td>
<td>0.80 [0.63, 1.02]</td>
</tr>
<tr>
<td><strong>1.4 Apixaban vs VKA</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aristole</td>
<td>79 2850</td>
<td>109 2828</td>
<td>0.71 [0.53, 0.95]</td>
</tr>
<tr>
<td>Aristole-J</td>
<td>0 45</td>
<td>2 23</td>
<td>0.05 [0.00, 0.50]</td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>2850</td>
<td>2881</td>
<td>0.72 [0.52, 0.93]</td>
</tr>
<tr>
<td>Heterogeneity: Chi² = 3.10, df = 1 (P = 0.08); I² = 68%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>1.5 Edoxaban 60mg vs VKA</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Engage-AF-Timi 48</td>
<td>198 2848</td>
<td>166 2820</td>
<td>0.81 [0.65, 1.03]</td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>2848</td>
<td>2820</td>
<td>0.81 [0.65, 1.03]</td>
</tr>
<tr>
<td><strong>1.6 Edoxaban 30mg vs VKA</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Engage-AF-Timi 48</td>
<td>184 2806</td>
<td>166 2820</td>
<td>1.12 [0.90, 1.39]</td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>2806</td>
<td>2820</td>
<td>1.12 [0.90, 1.39]</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Total Population (all ages)</th>
<th>DOAC Events Total</th>
<th>VKA Events Total</th>
<th>Peto Odds Ratio Peto, Fixed, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>2.1.1 Dabigatran 150mg vs VKA</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bibr-1048</td>
<td>0 58</td>
<td>1 62</td>
<td>0.14 [0.00, 7.29]</td>
</tr>
<tr>
<td>Petro</td>
<td>0 169</td>
<td>0 70</td>
<td>Not estimable</td>
</tr>
<tr>
<td>Re-ly</td>
<td>134 6076</td>
<td>202 6022</td>
<td>0.65 [0.53, 0.81]</td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>6303</td>
<td>6154</td>
<td>0.65 [0.52, 0.81]</td>
</tr>
<tr>
<td>Heterogeneity: Chi² = 0.57, df = 1 (P = 0.45); I² = 0%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>2.1.2 Dabigatran 110mg vs VKA</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bibr-1048</td>
<td>0 46</td>
<td>1 62</td>
<td>0.18 [0.00, 9.22]</td>
</tr>
<tr>
<td>Re-ly</td>
<td>185 6015</td>
<td>202 6022</td>
<td>0.60 [0.74, 1.11]</td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>6061</td>
<td>6084</td>
<td>0.90 [0.74, 1.10]</td>
</tr>
<tr>
<td>Heterogeneity: Chi² = 0.66, df = 1 (P = 0.42); I² = 0%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>2.1.3 Rivaroxaban vs VKA</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>J-Rocket-AF</td>
<td>11 637</td>
<td>22 637</td>
<td>0.50 [0.25, 1.01]</td>
</tr>
<tr>
<td>Rocket-AF</td>
<td>269 7081</td>
<td>306 7090</td>
<td>0.88 [0.74, 1.03]</td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>7718</td>
<td>7727</td>
<td>0.65 [0.72, 1.00]</td>
</tr>
<tr>
<td>Heterogeneity: Chi² = 2.31, df = 1 (P = 0.13); I² = 57%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>2.1.4 Apixaban vs VKA</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aristole</td>
<td>212 9120</td>
<td>265 9061</td>
<td>0.79 [0.66, 0.95]</td>
</tr>
<tr>
<td>Aristole-J</td>
<td>0 74</td>
<td>3 74</td>
<td>0.13 [0.01, 1.28]</td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>9194</td>
<td>9155</td>
<td>0.76 [0.65, 0.94]</td>
</tr>
<tr>
<td>Heterogeneity: Chi² = 2.37, df = 1 (P = 0.12); I² = 58%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>2.1.5 Edoxaban 60mg vs VKA</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Edox-P2</td>
<td>1 235</td>
<td>4 251</td>
<td>0.32 [0.05, 1.85]</td>
</tr>
<tr>
<td>Edox-J</td>
<td>0 131</td>
<td>0 129</td>
<td>Not estimable</td>
</tr>
<tr>
<td>Edox-P2A</td>
<td>0 80</td>
<td>0 75</td>
<td>Not estimable</td>
</tr>
<tr>
<td>Engage-AF-Timi 48</td>
<td>266 7035</td>
<td>340 7036</td>
<td>0.87 [0.74, 1.01]</td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>7481</td>
<td>7491</td>
<td>0.86 [0.73, 1.01]</td>
</tr>
<tr>
<td>Heterogeneity: Chi² = 1.23, df = 1 (P = 0.27); I² = 19%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>2.1.6 Edoxaban 30mg vs VKA</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Edox-P2</td>
<td>1 235</td>
<td>4 251</td>
<td>0.32 [0.05, 1.85]</td>
</tr>
<tr>
<td>Edox-J</td>
<td>0 131</td>
<td>0 129</td>
<td>Not estimable</td>
</tr>
<tr>
<td>Edox-P2A</td>
<td>0 79</td>
<td>0 75</td>
<td>Not estimable</td>
</tr>
<tr>
<td>Engage-AF-Timi 48</td>
<td>389 7034</td>
<td>340 7036</td>
<td>1.15 [0.90, 1.46]</td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>7479</td>
<td>7491</td>
<td>1.14 [0.98, 1.33]</td>
</tr>
<tr>
<td>Heterogeneity: Chi² = 2.04, df = 1 (P = 0.15); I² = 51%</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Elderly Population aged ≥75

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>DOAC Events</th>
<th>Total</th>
<th>VKA Events</th>
<th>Total</th>
<th>Peto Odds Ratio</th>
<th>Peto Odds Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1.2.1 Dabigatran 150mg vs VKA</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pooled Recover Studies</td>
<td>3</td>
<td>253</td>
<td>5</td>
<td>276</td>
<td>0.66 [0.16, 2.66]</td>
<td>0.66 [0.16, 2.66]</td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td></td>
<td>253</td>
<td>276</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Total Population (all ages)

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>DOAC Events</th>
<th>Total</th>
<th>VKA Events</th>
<th>Total</th>
<th>Peto Odds Ratio</th>
<th>Peto Odds Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>2.2.1 Dabigatran 150mg vs VKA</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Recover I</td>
<td>30</td>
<td>1274</td>
<td>27</td>
<td>1265</td>
<td>1.11 [0.65, 1.87]</td>
<td></td>
</tr>
<tr>
<td>Recover II</td>
<td>30</td>
<td>1279</td>
<td>28</td>
<td>1289</td>
<td>1.08 [0.64, 1.82]</td>
<td></td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>253</td>
<td>2554</td>
<td></td>
<td></td>
<td>1.09 [0.76, 1.58]</td>
<td></td>
</tr>
<tr>
<td>Heterogeneity: Chi² = 0.00, df = 1 (P = 0.95); I² = 0%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### 1.2.2 Apixaban vs VKA

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>DOAC Events</th>
<th>Total</th>
<th>VKA Events</th>
<th>Total</th>
<th>Peto Odds Ratio</th>
<th>Peto Odds Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amplify</td>
<td>7</td>
<td>389</td>
<td>13</td>
<td>360</td>
<td>0.50 [0.21, 1.21]</td>
<td></td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td></td>
<td>389</td>
<td>360</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### 2.2.2 Apixaban vs VKA

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>DOAC Events</th>
<th>Total</th>
<th>VKA Events</th>
<th>Total</th>
<th>Peto Odds Ratio</th>
<th>Peto Odds Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amplify</td>
<td>59</td>
<td>2509</td>
<td>71</td>
<td>2635</td>
<td>0.84 [0.59, 1.18]</td>
<td></td>
</tr>
<tr>
<td>Bottecelli-DVT</td>
<td>3</td>
<td>117</td>
<td>3</td>
<td>118</td>
<td>1.01 [0.20, 5.09]</td>
<td></td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>2726</td>
<td>2753</td>
<td></td>
<td></td>
<td>0.84 [0.60, 1.18]</td>
<td></td>
</tr>
<tr>
<td>Heterogeneity: Chi² = 0.05, df = 1 (P = 0.82); I² = 0%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### 1.2.3 Rivaroxaban vs VKA

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>DOAC Events</th>
<th>Total</th>
<th>VKA Events</th>
<th>Total</th>
<th>Peto Odds Ratio</th>
<th>Peto Odds Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>Einstein-DVT</td>
<td>4</td>
<td>215</td>
<td>10</td>
<td>225</td>
<td>0.43 [0.15, 1.25]</td>
<td></td>
</tr>
<tr>
<td>Einstein-PE</td>
<td>11</td>
<td>441</td>
<td>13</td>
<td>402</td>
<td>0.77 [0.34, 1.72]</td>
<td></td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>656</td>
<td>627</td>
<td></td>
<td></td>
<td>0.62 [0.33, 1.18]</td>
<td></td>
</tr>
<tr>
<td>Heterogeneity: Chi² = 0.70, df = 1 (P = 0.40); I² = 0%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### 2.2.3 Rivaroxaban vs VKA

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>DOAC Events</th>
<th>Total</th>
<th>VKA Events</th>
<th>Total</th>
<th>Peto Odds Ratio</th>
<th>Peto Odds Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>Einstein-DVT</td>
<td>38</td>
<td>1731</td>
<td>51</td>
<td>1718</td>
<td>0.70 [0.46, 1.07]</td>
<td></td>
</tr>
<tr>
<td>Einstein-DVT close study</td>
<td>3</td>
<td>115</td>
<td>7</td>
<td>101</td>
<td>0.38 [0.11, 1.34]</td>
<td></td>
</tr>
<tr>
<td>Einstein-PE</td>
<td>50</td>
<td>2419</td>
<td>44</td>
<td>2413</td>
<td>1.14 [0.76, 1.71]</td>
<td></td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>4265</td>
<td>4232</td>
<td></td>
<td></td>
<td>0.86 [0.65, 1.15]</td>
<td></td>
</tr>
<tr>
<td>Heterogeneity: Chi² = 4.34, df = 2 (P = 0.11); I² = 54%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### 1.2.4 Edoxaban 60mg vs VKA

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>DOAC Events</th>
<th>Total</th>
<th>VKA Events</th>
<th>Total</th>
<th>Peto Odds Ratio</th>
<th>Peto Odds Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hokusa-VTE</td>
<td>14</td>
<td>560</td>
<td>27</td>
<td>544</td>
<td>0.50 [0.27, 0.94]</td>
<td></td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>560</td>
<td>544</td>
<td></td>
<td></td>
<td>0.50 [0.27, 0.94]</td>
<td></td>
</tr>
</tbody>
</table>

### 2.2.4 Edoxaban 60mg vs VKA

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>DOAC Events</th>
<th>Total</th>
<th>VKA Events</th>
<th>Total</th>
<th>Peto Odds Ratio</th>
<th>Peto Odds Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hokusa-VTE</td>
<td>130</td>
<td>4118</td>
<td>146</td>
<td>4122</td>
<td>0.89 [0.70, 1.13]</td>
<td></td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>4118</td>
<td>4122</td>
<td></td>
<td></td>
<td>0.89 [0.70, 1.13]</td>
<td></td>
</tr>
</tbody>
</table>

Figure 4
### Elderly Population aged ≥75

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>DOAC</th>
<th>VKA</th>
<th>Peto Odds Ratio</th>
<th>Peto Odds Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Total</td>
<td>Total</td>
<td>Total</td>
<td>Total</td>
</tr>
<tr>
<td></td>
<td>Events</td>
<td>Events</td>
<td>Peto, Fixed</td>
<td>95% CI</td>
</tr>
<tr>
<td><strong>1.3.1 Dabigatran 150mg vs VKA</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pooling</td>
<td>6</td>
<td>231</td>
<td>10</td>
<td>262</td>
</tr>
<tr>
<td>Re-Ly</td>
<td>227</td>
<td>2145</td>
<td>188</td>
<td>2089</td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>2376</td>
<td>2359</td>
<td>1.18 [0.97, 1.44]</td>
<td>1.0 [0.79, 1.32]</td>
</tr>
<tr>
<td>Heterogeneity: CH² = 0.32, df = 1 (P = 0.57); I² = 0%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| **1.3.2 Dabigatran 150mg vs VKA** | | | | | | |
| Pooling | 187 | 2026 | 188 | 2088 | 1.03 [0.83, 1.27] | 1.0 [0.80, 1.29] |
| Subtotal (95% CI) | 2028 | 2088 | 1.03 [0.83, 1.27] | 1.0 [0.80, 1.29] |

| **1.3.3 Rivaroxaban vs VKA** | | | | | | |
| Einstein-DVT | 3 | 219 | 5 | 223 | 0.62 [0.15, 2.52] | 1.0 [0.23, 4.40] |
| Einstein-PE | 5 | 410 | 23 | 401 | 0.24 [0.11, 0.55] | 0.5 [0.20, 1.32] |
| J-Rocket-AF | 14 | 206 | 10 | 207 | 1.43 [0.63, 3.26] | 1.4 [0.62, 3.67] |
| ROCKET-AF | 203 | 2608 | 179 | 2702 | 1.15 [0.82, 1.62] | 1.0 [0.76, 1.33] |
| Heterogeneity: CH² = 0.54, df = 3 (P = 0.69); I² = 6% | | | | |

| **1.3.4 Apixaban vs VKA** | | | | | | |
| Amplitude | 4 | 366 | 16 | 370 | 0.27 [0.11, 0.68] | 0.3 [0.13, 0.71] |
| Arista-IT | 151 | 2336 | 224 | 2819 | 0.60 [0.53, 0.68] | 0.6 [0.53, 0.70] |
| Heterogeneity: CH² = 0.66, df = 1 (P = 0.05); I² = 72% | | | | |

| **1.3.5 Edoxaban 60mg vs VKA** | | | | | | |
| ENGAGE-AF-TI 48 | 214 | 2848 | 257 | 2820 | 0.81 [0.67, 0.98] | 1.0 [0.88, 1.21] |
| Subtotal (95% CI) | 2848 | 2820 | 0.81 [0.67, 0.98] | 1.0 [0.88, 1.21] |

| **1.3.6 Edoxaban 30mg vs VKA** | | | | | | |
| ENGAGE-AF-TI 48 | 121 | 2808 | 257 | 2820 | 0.46 [0.38, 0.57] | 0.5 [0.40, 0.67] |
| Subtotal (95% CI) | 2806 | 2820 | 0.46 [0.38, 0.57] | 0.5 [0.40, 0.67] |

### Total Population (all ages)

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>DOAC</th>
<th>VKA</th>
<th>Peto Odds Ratio</th>
<th>Peto Odds Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Events</td>
<td>Events</td>
<td>Total</td>
<td>Total</td>
</tr>
<tr>
<td></td>
<td>Peto, Fixed</td>
<td>95% CI</td>
<td>Peto, Fixed</td>
<td>95% CI</td>
</tr>
<tr>
<td><strong>2.3.1 Dabigatran 150mg vs VKA</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BLIB-104</td>
<td>1</td>
<td>58</td>
<td>2</td>
<td>62</td>
</tr>
<tr>
<td>Re-Ly</td>
<td>0</td>
<td>169</td>
<td>0</td>
<td>70</td>
</tr>
<tr>
<td>Heterogeneity: CH² = 1.16, df = 3 (P = 0.76); I² = 0%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| **2.3.2 Dabigatran 110mg vs VKA** | | | | | | |
| Re-Ly | 0 | 46 | 2 | 62 | 0.17 [0.01, 2.98] | 0.17 [0.01, 2.98] |
| Heterogeneity: CH² = 1.14, df = 1 (P = 0.28); I² = 13% | | | | |

| **2.3.3 Rivaroxaban vs VKA** | | | | | | |
| Einstein-DVT | 14 | 1718 | 20 | 1711 | 0.70 [0.35, 1.37] | 0.7 [0.35, 1.37] |
| Einstein-PE | 1 | 135 | 2 | 137 | 0.52 [0.05, 5.03] | 0.52 [0.05, 5.03] |
| J-Rocket-AF | 26 | 2412 | 52 | 2405 | 0.51 [0.32, 0.79] | 0.51 [0.32, 0.79] |
| Rocket-AF | 35 | 639 | 30 | 639 | 0.83 [0.48, 1.42] | 0.83 [0.48, 1.42] |
| Subtotal (95% CI) | 395 | 7115 | 386 | 7125 | 1.03 [0.05, 1.98] | 1.03 [0.05, 1.98] |
| Heterogeneity: CH² = 10.01, df = 4 (P = 0.04); I² = 60% | | | | |

| **2.3.4 Apixaban vs VKA** | | | | | | |
| Amplitude | 15 | 2678 | 49 | 2689 | 0.64 [0.21, 0.68] | 0.6 [0.21, 0.68] |
| Arista-IT | 327 | 5050 | 462 | 5052 | 0.70 [0.60, 0.83] | 0.7 [0.60, 0.83] |
| Heterogeneity: CH² = 0.35, df = 3 (P = 0.03); I² = 68% | | | | |

| **2.3.5 Edoxaban 60mg vs VKA** | | | | | | |
| EDox-2 | 1 | 234 | 1 | 250 | 1.07 [0.67, 1.71] | 1.07 [0.67, 1.71] |
| EDox-J | 2 | 230 | 0 | 125 | 7.17 [0.46, 115.25] | 7.17 [0.46, 115.25] |
| EDox-P2A | 0 | 80 | 2 | 75 | 0.12 [0.02, 0.76] | 0.12 [0.02, 0.76] |
| Hokusai-VTE | 117 | 7012 | 124 | 7012 | 0.72 [0.80, 0.98] | 0.72 [0.80, 0.98] |
| Subtotal (95% CI) | 11574 | 11584 | 0.79 [0.70, 0.90] | 0.79 [0.70, 0.90] |

| **2.3.6 Edoxaban 30mg vs VKA** | | | | | | |
| EDox-P2 | 0 | 235 | 1 | 250 | 0.14 [0.00, 7.20] | 0.14 [0.00, 7.20] |
| EDox-J | 0 | 130 | 0 | 125 | Not estimable | |
| EDox-P2A | 0 | 79 | 2 | 75 | 0.13 [0.01, 2.04] | 0.13 [0.01, 2.04] |
| Hokusai-VTE | 254 | 7002 | 524 | 7012 | 0.48 [0.42, 0.56] | 0.48 [0.42, 0.56] |
| Subtotal (95% CI) | 7446 | 7462 | 0.48 [0.41, 0.55] | 0.48 [0.41, 0.55] |

Heterogeneity: CH² = 1.24, df = 2 (P = 0.54); I² = 0%
<table>
<thead>
<tr>
<th>Outcome</th>
<th>DOAC</th>
<th>Studies</th>
<th>OR (95% CI)</th>
<th>Studies</th>
<th>OR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>GIB</td>
<td>Dabigatran 150mg</td>
<td>1</td>
<td>1.78 (1.35, 2.35)</td>
<td>3</td>
<td>1.49 (1.24, 1.79)</td>
</tr>
<tr>
<td></td>
<td>Dabigatran 110mg</td>
<td>1</td>
<td>1.40 (1.04, 1.90)</td>
<td>1</td>
<td>1.09 (1.01, 1.21)</td>
</tr>
<tr>
<td></td>
<td>Rivaroxaban</td>
<td>0</td>
<td>1.38 (1.17, 1.62)</td>
<td>4</td>
<td>1.38 (1.17, 1.62)</td>
</tr>
<tr>
<td></td>
<td>Apixaban</td>
<td>0</td>
<td>0.82 (0.64, 1.05)</td>
<td>3</td>
<td>0.82 (0.64, 1.05)</td>
</tr>
<tr>
<td></td>
<td>Edoxaban 60mg</td>
<td>0</td>
<td>1.23 (1.01, 1.49)</td>
<td>1</td>
<td>1.23 (1.01, 1.49)</td>
</tr>
<tr>
<td></td>
<td>Edoxaban 30mg</td>
<td>0</td>
<td>0.68 (0.54, 0.85)</td>
<td>1</td>
<td>0.68 (0.54, 0.85)</td>
</tr>
<tr>
<td></td>
<td>Dabigatran 150mg</td>
<td>1</td>
<td>0.43 (0.26, 0.72)</td>
<td>2</td>
<td>0.42 (0.30, 0.65)</td>
</tr>
<tr>
<td>ICB</td>
<td>Dabigatran 110mg</td>
<td>1</td>
<td>0.36 (0.22, 0.61)</td>
<td>1</td>
<td>0.34 (0.23, 0.49)</td>
</tr>
<tr>
<td></td>
<td>Rivaroxaban</td>
<td>3</td>
<td>0.77 (0.48, 1.23)</td>
<td>5</td>
<td>0.60 (0.45, 0.81)</td>
</tr>
<tr>
<td></td>
<td>Apixaban</td>
<td>1</td>
<td>0.30 (0.24, 0.59)</td>
<td>3</td>
<td>0.44 (0.33, 0.59)</td>
</tr>
<tr>
<td></td>
<td>Edoxaban 60mg</td>
<td>0</td>
<td>1.25 (0.90, 1.75)</td>
<td>2</td>
<td>1.25 (0.90, 1.75)</td>
</tr>
<tr>
<td></td>
<td>Edoxaban 30mg</td>
<td>0</td>
<td>0.30 (0.26, 0.47)</td>
<td>0</td>
<td>0.30 (0.26, 0.47)</td>
</tr>
<tr>
<td>ORB</td>
<td>Dabigatran 150mg</td>
<td>2</td>
<td>0.73 (0.41, 1.26)</td>
<td>4</td>
<td>0.64 (0.52, 0.80)</td>
</tr>
<tr>
<td></td>
<td>Dabigatran 110mg</td>
<td>0</td>
<td>1.30 (0.84, 2.00)</td>
<td>1</td>
<td>0.52 (0.31, 0.88)</td>
</tr>
<tr>
<td></td>
<td>Rivaroxaban</td>
<td>4</td>
<td>1.10 (0.62, 1.94)</td>
<td>5</td>
<td>1.01 (0.94, 1.08)</td>
</tr>
<tr>
<td></td>
<td>Apixaban</td>
<td>1</td>
<td>1.04 (0.54, 1.97)</td>
<td>4</td>
<td>0.88 (0.38, 2.10)</td>
</tr>
<tr>
<td></td>
<td>Edoxaban 60mg</td>
<td>1</td>
<td>0.80 (0.57, 1.13)</td>
<td>5</td>
<td>0.83 (0.77, 0.89)</td>
</tr>
<tr>
<td></td>
<td>Edoxaban 30mg</td>
<td>0</td>
<td>0.59 (0.55, 0.64)</td>
<td>1</td>
<td>0.59 (0.55, 0.64)</td>
</tr>
<tr>
<td>FB</td>
<td>Dabigatran 150mg</td>
<td>1</td>
<td>0.82 (0.48, 1.72)</td>
<td>3</td>
<td>0.70 (0.44, 1.12)</td>
</tr>
<tr>
<td></td>
<td>Dabigatran 110mg</td>
<td>1</td>
<td>0.72 (0.26, 2.03)</td>
<td>1</td>
<td>0.62 (0.30, 0.96)</td>
</tr>
<tr>
<td></td>
<td>Rivaroxaban</td>
<td>4</td>
<td>0.32 (0.09, 1.09)</td>
<td>5</td>
<td>0.48 (0.32, 0.71)</td>
</tr>
<tr>
<td></td>
<td>Apixaban</td>
<td>1</td>
<td>0.80 (0.22, 2.94)</td>
<td>3</td>
<td>0.69 (0.20, 2.16)</td>
</tr>
<tr>
<td></td>
<td>Edoxaban 60mg</td>
<td>0</td>
<td>0.62 (0.35, 0.86)</td>
<td>3</td>
<td>0.62 (0.35, 0.86)</td>
</tr>
<tr>
<td></td>
<td>Edoxaban 30mg</td>
<td>0</td>
<td>0.39 (0.29, 0.60)</td>
<td>2</td>
<td>0.39 (0.29, 0.60)</td>
</tr>
</tbody>
</table>

Figure 6
Efficacy and Harms of Direct Oral Anticoagulants in the Elderly for Stroke Prevention in Atrial Fibrillation and Secondary Prevention of Venous Thromboembolism: Systematic Review and Meta-Analysis
Manuj Sharma, Victoria R. Cornelius, Jignesh P, Patel, J. Graham Davies and Mariam Molokhia

Circulation. published online May 20, 2015:
Circulation is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2015 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circ.ahajournals.org/content/early/2015/05/15/CIRCULATIONAHA.114.013267

Data Supplement (unedited) at:
http://circ.ahajournals.org/content/suppl/2015/05/18/CIRCULATIONAHA.114.013267.DC1

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation is online at:
http://circ.ahajournals.org/subscriptions/
Supplemental Material

Supplemental Methods

Supplemental Methods 1a. Additional Information

Supplemental Methods 2a. Search Strategy in EMBASE

Supplemental Methods 2b. Search Strategy in MEDLINE

Supplemental Methods 2c. Search Strategy in CENTRAL

Table S1 Rationale for exclusion of studies following review of full publications

Table S2 Mean time in therapeutic range (TTR) on vitamin k antagonist and concomitant aspirin usage for included studies.

Table S3 Role of Funder in individual studies

Table S4 Characteristics of included studies for DOACs in AF and VTE (expanded table)

Figure S1. PRISMA Flow Diagram – Study Identification, Selection and Exclusions

Figure S2. Forest Plots for risk of Stroke or Systemic Embolism in Elderly and Total Population

Figure S3. Forest Plots for risk of Recurrent VTE in Elderly and Total Population

Figure S4. Forest Plots for risk of Major Bleeding in Elderly and Total Population

Figure S5. Forest Plots for risk of Gastrointestinal Bleeding in Elderly and Total Population

Figure S6. Forest Plots for risk of Intracranial Bleeding in Elderly and Total Population

Figure S7. Forest Plots for risk of Clinically Relevant Bleeding in Elderly and Total Population

Figure S8. Forest Plots for risk of Fatal Bleeding in Elderly and Total Population

Figure S9. Forest Plots for risk of All Cause Death in AF in Elderly and Total Population

Figure S10. Forest Plots for risk of All Cause Death in VTE studies in Total Population

Figure S11. Forest Plots for risk of Stroke or Systemic Embolism in Elderly and <75 Population

Figure S12. Forest Plots for risk of VTE in Elderly and <75 Population

Figure S13. Forest Plots for risk of Major Bleeding in Elderly and <75 Population

Figure S14. Forest Plots for risk of Gastrointestinal Bleeding in Elderly and <75 Population

Figure S15. Forest Plots for risk of Intracranial Bleeding in Elderly and <75 Population

Figure S16. Forest Plots for risk of Clinically Relevant Bleeding in Elderly and <75 Population

Figure S17. Forest Plots for risk of Fatal Bleeding in Elderly and <75 Population

Figure S18. Forest Plots for risk of All Cause Death in AF in Elderly and <75 Population

Figure S19. Funnel Plots for Stroke or Systemic Embolism in Elderly and Total population

Figure S20. Funnel Plots for risk of Recurrent VTE in Elderly and Total population

Supplemental References
Supplemental Methods

Supplemental Methods 1a. Additional Information.

Additional information gathered on the role of funders in the individual studies and characteristics of included studies are detailed in Supplemental Table S3 and Table S4 respectively.

Original forest plots for all outcomes presented in the main manuscript are detailed in Supplemental Figures S2-S8. Additional forest plots detailing data on risks of all death can be found in Figure S9-S10. Forest plots containing data from the <75 and ≥75 populations can be found in Figures S11-S18.

Additional funnel plots for risk of stroke or systemic embolism and venous thromboembolism in the elderly and total population are presented in Supplemental Figure S19-S20.
Supplemental Methods 2a. Search Strategy in EMBASE.

Ovid Technologies, Inc. Search limit to english language Database: Embase Classic+Embase <1947 to 2013 November 21> Search Strategy:
-----------------------------------------------------------------------------------
1 EXP dabigatran etexilate/ or EXP dabigatran/ or dabigatran.mp. (4628)
2 rivaroxaban.mp. or EXP rivaroxaban/ (3840)
3 apixaban.mp. or EXP apixaban/ (2350)
4 edoxaban.mp. or EXP edoxaban/ (558)
5 EXP thrombin inhibitor/ (35324)
6 ((direct adj3 thrombin adj3 inhib$) or DTI).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword] (10140)
7 xaban$.mp. (12)
8 EXP blood clotting factor 10a inhibitor/ (9874)
9 ((factor Xa or factor 10a or fXa) adj3 inhib$).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword] (4755)
10 (factor 2a inhib$ or factor IIa inhib$ or f2a inhib$).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword] (59)
11 (Pra?ax$ or Xarelto or Eliqu?s or Lixiana).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword] (795)
12 (NOAC or (anticoagulant$ adj3 oral adj3 new) or (anticoagulant$ adj3 oral adj3 novel)).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword] (1435)
13 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 (48838)
14 deep vein thrombosis.mp. or EXP deep vein thrombosis/ (41442)
15 (DVT or thromboembolism or venous thromboembolism or VTE).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword] (89387)
16 EXP lung embolism/ (64280)
17 (lung embol$ or pulmonary embol$ or PE).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword] (100305)
18 EXP heart atrium fibrillation/ (77878)
19 EXP heart atrium flutter/ (9788)
20 ((atrial or auricular) adj5 (fibrillation$ or flutter$)).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword] (66474)
21 (AF or NVAF).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword] (51520)
22 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 (296005)
23 13 and 22 (12898)
24 Clinical trial/ (898699)
25 randomized controlled trial/ (362954)
26 Randomization/ (64197)
27 Single blind procedure/ (18566)
28 Double blind procedure/ (123454)
29 Crossover procedure/ (39339)
30 Placebo/ (246077)
Randomi?ed controlled trial$.tw. (96717)
Rct.tw. (13134)
Random allocation.tw. (1390)
Randomly allocated.tw. (20328)
Allocated randomly.tw. (1973)
(allocated adj2 random).tw. (892)
Single blind$.tw. (14467)
Double blind$.tw. (151887)
((treble or triple) adj blind$).tw. (383)
Placebo$.tw. (207389)
Prospective study/ (256675)
or/24-41 (1422876)
Case study/ (31643)
Case report.tw. (282476)
Abstract report/ or letter/ (912074)
or/43-45 (1220663)
42 not 46 (1384928)
23 and 47 (4115)
limit 48 to last 20 years (4092)
limit 49 to human (3978)
limit 50 to english language (3615)

***************************
Supplemental Methods 2b. Search Strategy in MEDLINE.

Ovid Technologies, Inc. Search limit to english language

Database: Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations and Ovid MEDLINE(R) <1946 to Present> Search Strategy:

Ovid MEDLINE(R) database

1 dabigatran.mp. (1957)
2 rivaroxaban.mp. (1283)
3 apixaban.mp. (758)
4 edoxaban.mp. (161)
5 (NOAC or (anticoagulant$ adj3 oral adj3 new) or (anticoagulant$ adj3 oral adj3 novel)).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier] (999)
6 exp Thrombin/ad, ai, tu, th [Administration & Dosage, Antagonists & Inhibitors, Therapeutic Use, Therapy] (5064)
7 ((direct adj3 thrombin adj3 inhib$) or DTI).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier] (7055)
8 xaban$.mp. (7)
9 exp Factor Xa/ad, ai, tu [Administration & Dosage, Antagonists & Inhibitors, Therapeutic Use] (2291)
10 ((factor Xa or factor 10a or fXa) adj3 inhib$).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier] (2486)
11 ((factor 2a or factor IIa or f2a) adj3 inhib$).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier] (61)
12 (Pra?ax$ or Xarelto or Eliqu?is or Lixiana).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier] (150)
13 exp Venous Thrombosis/ (44632)
14 ("deep vein thrombosis" or DVT or thromboembolism or venous thromboembolism or VTE).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier] (48776)
15 exp Pulmonary Embolism/ (31309)
16 exp Venous Thromboembolism/ (4499)
17 (lung embol$ or pulmonary embol$ or PE).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier] (62301)
18 exp Atrial Fibrillation/ (34118)
19 exp Atrial Flutter/ (4965)
20 ((atrial or auricular) adj5 (fibrillation$ or flutter$)).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier] (50348)
21 (AF or NVAF).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier] (35889)
22 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 (16237)
23 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 (196699)
24 22 and 23 (3363)
### Supplemental Methods 2c. Search Strategy in CENTRAL.

<table>
<thead>
<tr>
<th>ID</th>
<th>Search</th>
</tr>
</thead>
<tbody>
<tr>
<td>#1</td>
<td>dabigatran</td>
</tr>
<tr>
<td>#2</td>
<td>rivaroxaban</td>
</tr>
<tr>
<td>#3</td>
<td>apixaban</td>
</tr>
<tr>
<td>#4</td>
<td>edoxaban</td>
</tr>
<tr>
<td>#5</td>
<td>((direct adj3 thrombin adj3 inhib$) or DTI)</td>
</tr>
<tr>
<td>#6</td>
<td>MeSH descriptor: [Antithrombins] explode all trees</td>
</tr>
<tr>
<td>#7</td>
<td>xaban$</td>
</tr>
<tr>
<td>#8</td>
<td>MeSH descriptor: [Blood Coagulation Factor Inhibitors] explode all trees</td>
</tr>
<tr>
<td>#9</td>
<td>((factor Xa or factor 10a or fXa or autoprothrombin c or thrombokinase) adj5 inhib$)</td>
</tr>
<tr>
<td>#10</td>
<td>(factor 2a inhib$ or factor Ila inhib$ or f2a inhib$)</td>
</tr>
<tr>
<td>#11</td>
<td>Pra?ax$ or Xarelto or Eliqu? or Lixiana</td>
</tr>
<tr>
<td>#12</td>
<td>#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11</td>
</tr>
<tr>
<td>#13</td>
<td>(NOAC or (anticoagulant$ adj3 oral adj3 new) or (anticoagulant$ adj3 oral adj3 novel))</td>
</tr>
<tr>
<td>#14</td>
<td>#12 or #13</td>
</tr>
<tr>
<td>#15</td>
<td>MeSH descriptor: [Embolism and Thrombosis] explode all trees</td>
</tr>
<tr>
<td>#16</td>
<td>MeSH descriptor: [Anticoagulants] explode all trees</td>
</tr>
<tr>
<td>#17</td>
<td>#14 or #16</td>
</tr>
<tr>
<td>#18</td>
<td>(&quot;deep vein thrombosis OR DVT&quot; or thromboembolism or venous thromboembolism or VTE)</td>
</tr>
<tr>
<td>#19</td>
<td>(lung embol$ or pulmonary embol$ or PE)</td>
</tr>
<tr>
<td>#20</td>
<td>MeSH descriptor: [Atrial Fibrillation] explode all trees</td>
</tr>
<tr>
<td>#21</td>
<td>MeSH descriptor: [Atrial Flutter] explode all trees</td>
</tr>
<tr>
<td>#22</td>
<td>((atrial or auricular) adj5 (fibrillation$ or flutter$))</td>
</tr>
<tr>
<td>#23</td>
<td>(AF or NVAF)</td>
</tr>
<tr>
<td>#24</td>
<td>#15 or #18 or #19 or #20 or #21 or #22 or #23</td>
</tr>
<tr>
<td>#25</td>
<td>#17 and #24</td>
</tr>
</tbody>
</table>
Table S1 Rationale for exclusion of studies following review of full publications.

<table>
<thead>
<tr>
<th>Studies excluded</th>
<th>DOAC</th>
<th>Rationale for exclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Re-lyable</td>
<td>Dabigatran</td>
<td>Extension of completed phase III Re-ly study for additional follow up only. Observational study.</td>
</tr>
<tr>
<td>Re-medy</td>
<td>Dabigatran</td>
<td>Extension study of completed phase III Recover I and Recover II studies in patients who had already received 3 months treatment for acute VTE.</td>
</tr>
<tr>
<td>Re-sonate</td>
<td>Dabigatran</td>
<td>Extension study as per Re-medy. VKA was not the comparator.</td>
</tr>
<tr>
<td>Einstein-Ext</td>
<td>Rivaroxaban</td>
<td>Extension study for phase III Einstein DVT and PE studies in patients who had already received 6 months of treatment for acute VTE. VKA was not the comparator.</td>
</tr>
<tr>
<td>Odixa DVT</td>
<td>Rivaroxaban</td>
<td>Phase II study with no arm that used a dose of rivaroxaban that was subsequently used in phase III studies.</td>
</tr>
<tr>
<td>NCT00973245</td>
<td>Rivaroxaban</td>
<td>Study was less than 3 months in duration.</td>
</tr>
<tr>
<td>NCT00973323</td>
<td>Rivaroxaban</td>
<td>Study was less than 3 months in duration.</td>
</tr>
<tr>
<td>Averroes</td>
<td>Apixaban</td>
<td>VKA was not the comparator.</td>
</tr>
<tr>
<td>Amplify-Ext</td>
<td>Apixaban</td>
<td>Extension study of previously completed phase III Amplify study. VKA was not used as comparator.</td>
</tr>
</tbody>
</table>
Table S2 Mean time in therapeutic range (TTR) on vitamin k antagonist and concomitant aspirin usage for included studies.

<table>
<thead>
<tr>
<th>Study</th>
<th>Mean TTR on VKA (%)</th>
<th>Concomitant aspirin use during study %</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>DOAC</td>
<td>VKA</td>
</tr>
<tr>
<td>DABIGATRAN</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bibr 1048, 2005</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Petro, 2007</td>
<td>57.2</td>
<td>40.8</td>
</tr>
<tr>
<td>Re-ly, 2009</td>
<td>64</td>
<td>20.3</td>
</tr>
<tr>
<td>Recover I, 2010</td>
<td>60</td>
<td>NA</td>
</tr>
<tr>
<td>Recover II, 2013</td>
<td>56.9</td>
<td>10.2</td>
</tr>
<tr>
<td>APIXABAN</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aristotle, 2011</td>
<td>62.2</td>
<td>NA</td>
</tr>
<tr>
<td>Aristotle-J, 2011</td>
<td>NA</td>
<td>28.2</td>
</tr>
<tr>
<td>Botticelli-DVT, 2008</td>
<td>57</td>
<td>NA</td>
</tr>
<tr>
<td>Amplify, 2013</td>
<td>61</td>
<td>NA</td>
</tr>
<tr>
<td>RIVAROXABAN</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rocket-AF, 2011</td>
<td>55</td>
<td>NA</td>
</tr>
<tr>
<td>J-Rocket AF, 2011</td>
<td>65</td>
<td>NA</td>
</tr>
<tr>
<td>Einstein-DVT Dose Study, 2008</td>
<td>50.3</td>
<td>NA</td>
</tr>
<tr>
<td>Einstein-DVT, 2010</td>
<td>57.7</td>
<td>NA</td>
</tr>
<tr>
<td>Einstein-PE, 2012</td>
<td>62.7</td>
<td>NA</td>
</tr>
<tr>
<td>EDOXABAN</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Edox-P2, 2010</td>
<td>49.7</td>
<td>NA</td>
</tr>
<tr>
<td>Edox-P2A, 2010</td>
<td>45.1</td>
<td>41.9</td>
</tr>
<tr>
<td>Edox-J, 2012</td>
<td>73 IF &lt;70 years</td>
<td>83 IF ≥70 years</td>
</tr>
<tr>
<td>Engage-AF-Timi 48, 2013</td>
<td>64.9</td>
<td>NA</td>
</tr>
<tr>
<td>Hokusai-VTE, 2013</td>
<td>63.5</td>
<td>NA</td>
</tr>
</tbody>
</table>

NA=Not available
TTR=Time in therapeutic range
Table S3 Role of Funder in individual studies.

<table>
<thead>
<tr>
<th>Study</th>
<th>Funded by Manufacturer</th>
<th>Role in Design</th>
<th>Role in Analysis</th>
<th>Control over Publication</th>
</tr>
</thead>
<tbody>
<tr>
<td>DABIGATRAN</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bibr 1048, 2005</td>
<td>Y</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td>Petro, 2007</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>NR</td>
</tr>
<tr>
<td>Re-ly, 2009</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
</tr>
<tr>
<td>Recover I, 2010</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>NR</td>
</tr>
<tr>
<td>Recover II, 2013</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>NR</td>
</tr>
<tr>
<td>APIXABAN</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aristotle, 2011</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>NR</td>
</tr>
<tr>
<td>Aristotle-J, 2011</td>
<td>Y</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td>Botticelli-DVT, 2008</td>
<td>Y</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td>Amplify, 2013</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
</tr>
<tr>
<td>RIVAROXABAN</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rocket-AF, 2011</td>
<td>Y</td>
<td>NR</td>
<td>N</td>
<td>N</td>
</tr>
<tr>
<td>J-Rocket AF, 2011</td>
<td>Y</td>
<td>N</td>
<td>Y</td>
<td>NR</td>
</tr>
<tr>
<td>Einstein-DVT, Dose Study, 2008</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
</tr>
<tr>
<td>Einstein-DVT, 2010</td>
<td>Y</td>
<td>NR</td>
<td>NR</td>
<td>Y</td>
</tr>
<tr>
<td>Einstein-PE, 2012</td>
<td>Y</td>
<td>NR</td>
<td>NR</td>
<td>Y</td>
</tr>
<tr>
<td>EDOXABAN</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Edox-P2, 2010</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>NR</td>
</tr>
<tr>
<td>Edox-P2A, 2010</td>
<td>Y</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td>Edox-J, 2012</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
</tr>
<tr>
<td>Engage-AF-Timi 48, 2013</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>N</td>
</tr>
<tr>
<td>Hokusai-VTE, 2013</td>
<td>Y</td>
<td>Y</td>
<td>NR</td>
<td>NR</td>
</tr>
</tbody>
</table>

Y=Yes
N=No
NR=Not Reported
Table S4 Characteristics of included studies for DOACs in AF and VTE (expanded table).

<table>
<thead>
<tr>
<th>Study</th>
<th>Standard Dose</th>
<th>Phase</th>
<th>Inclusion Criteria</th>
<th>Target INR range</th>
<th>Duration/Median Follow up* (months)</th>
<th>Heparin ≥5 days permitted prior to DOAC/VKA</th>
</tr>
</thead>
<tbody>
<tr>
<td>DABIGATRAN</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bibr 1048, 2005</td>
<td>110mg BD or 150mg BD</td>
<td>II</td>
<td>Aged≥20, NVAF and CHADS$_2$ of ≥1 or CAD</td>
<td>2-3</td>
<td>3</td>
<td>N</td>
</tr>
<tr>
<td>Petro, 2007</td>
<td>150mg BD extracted</td>
<td>II</td>
<td>Aged≥18, NVAF and CHADS$_2$ of ≥1 or CAD</td>
<td>2-3</td>
<td>3</td>
<td>N</td>
</tr>
<tr>
<td>Re-ly, 2009</td>
<td>110mg or 150mg BD</td>
<td>III</td>
<td>Aged≥18, NVAF and CHADS$_2$ of ≥1 or CAD</td>
<td>2-3</td>
<td>24*</td>
<td>N</td>
</tr>
<tr>
<td>Recover I, 2010</td>
<td>150mg BD</td>
<td>III</td>
<td>Aged≥18 and confirmed VTE</td>
<td>2-3</td>
<td>6</td>
<td>Y</td>
</tr>
<tr>
<td>Recover II, 2013</td>
<td>150mg BD</td>
<td>III</td>
<td>Aged≥18 and confirmed VTE</td>
<td>2-3</td>
<td>6</td>
<td>Y</td>
</tr>
<tr>
<td>ARIXABAN</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aristotle, 2011</td>
<td>5mg BD</td>
<td>III</td>
<td>Aged≥18, NVAF and CHADS$_2$ of ≥1</td>
<td>2-3</td>
<td>21.6*</td>
<td>N</td>
</tr>
<tr>
<td>Aristotle-J, 2011</td>
<td>5mg BD extracted</td>
<td>II</td>
<td>Aged≥20, NVAF and CHADS$_2$ of ≥1</td>
<td>2-3 and 1.6–2.6 if aged≥70</td>
<td>3</td>
<td>N</td>
</tr>
<tr>
<td>Botticelli-DVT, 2008</td>
<td>5mg BD</td>
<td>II</td>
<td>Aged≥18 and confirmed DVT without PE</td>
<td>2-3</td>
<td>3</td>
<td>N</td>
</tr>
<tr>
<td>Amplify, 2013</td>
<td>10mg BD for 7 days then 5mg BD</td>
<td>III</td>
<td>Aged≥18 and confirmed VTE</td>
<td>2-3</td>
<td>6</td>
<td>N</td>
</tr>
<tr>
<td>RIVAROXABAN</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rocket-AF, 2011</td>
<td>20mg OD</td>
<td>III</td>
<td>Aged≥18, NVAF and CHADS$_2$ of ≥2</td>
<td>2-3</td>
<td>23.2*</td>
<td>N</td>
</tr>
<tr>
<td>J-Rocket AF, 2011</td>
<td>15mg OD</td>
<td>III</td>
<td>Japanese, Aged≥20, NVAF and CHADS$_2$ of ≥2</td>
<td>2-3 and 1.6–2.6 if aged≥70</td>
<td>30</td>
<td>N</td>
</tr>
<tr>
<td>Einstein-DVT, 2008</td>
<td>20mg OD extracted</td>
<td>II</td>
<td>Aged≥18 and confirmed DVT</td>
<td>2-3</td>
<td>3</td>
<td>N</td>
</tr>
<tr>
<td>Einstein-DVT, 2010</td>
<td>15mg BD for 21 days then 20mg OD</td>
<td>III</td>
<td>Aged≥18 and confirmed DVT without PE</td>
<td>2-3</td>
<td>3, 6 or 12</td>
<td>N</td>
</tr>
<tr>
<td>Einstein-PE, 2012</td>
<td>15mg BD for 21 days then 20mg OD</td>
<td>III</td>
<td>Aged≥18 and confirmed PE with/without DVT</td>
<td>2-3</td>
<td>3, 6 or 12</td>
<td>N</td>
</tr>
<tr>
<td>EDOXABAN</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Edox-P2, 2010</td>
<td>30mg and 60mg OD extracted</td>
<td>II</td>
<td>Aged≥20, NVAF and CHADS$_2$ of ≥2</td>
<td>2-3</td>
<td>3</td>
<td>N</td>
</tr>
<tr>
<td>Edox-P2A, 2010</td>
<td>30mg OD and 60mg OD</td>
<td>II</td>
<td>Aged≥20, NVAF and CHADS$_2$ of ≥1</td>
<td>2-3</td>
<td>3</td>
<td>N</td>
</tr>
<tr>
<td>Study</td>
<td>Standard Dose</td>
<td>Phase</td>
<td>Inclusion Criteria</td>
<td>Target INR range</td>
<td>Duration/Median Follow up* (months)</td>
<td>Heparin ≥5 days permitted prior to DOAC/VKA</td>
</tr>
<tr>
<td>----------------</td>
<td>-------------------------------</td>
<td>-------</td>
<td>-------------------------------------</td>
<td>------------------</td>
<td>------------------------------------</td>
<td>-----------------------------------------------</td>
</tr>
<tr>
<td>Edox-I, 2012</td>
<td>30mg and 60mg OD extracted</td>
<td>II</td>
<td>Aged≥20, NVAF and CHADS₂ of ≥1</td>
<td>2-3 and 1.6–2.6 if aged≥70</td>
<td>3</td>
<td>N</td>
</tr>
<tr>
<td>Engage-AF-Timi 48, 2013</td>
<td>30mg OD or 60mg OD</td>
<td>III</td>
<td>Aged≥21, NVAF and CHADS₂ of ≥2</td>
<td>2-3</td>
<td>33.6*</td>
<td>N</td>
</tr>
<tr>
<td>Hokusai-VTE, 2013</td>
<td>60mg OD</td>
<td>III</td>
<td>Aged≥18 and confirmed VTE</td>
<td>2-3</td>
<td>3 to 12</td>
<td>Y</td>
</tr>
</tbody>
</table>

OD= Once daily  
BD= Twice daily  
NVAF= Non-valvular atrial fibrillation  
VTE= Venous Thromboembolism  
DVT= Deep-vein thrombosis  
PE= Pulmonary Embolism  
CAD= Coronary Artery Disease
Records identified through database searching (n = 7341)*

Additional records identified through other sources (n = 6)

Records after 1419 duplicates removed (n = 5928)

Records screened (n = 5928)

Records excluded (n = 5901)

Full-text articles assessed for eligibility (n = 27)

Studies included in qualitative synthesis (n = 19)

Studies included in quantitative synthesis (meta-analysis) (n = 19)

Full-text articles excluded, with reasons (n = 8)
- 4: Trial extension only
- 1: Wrong comparator
- 1: Phase II without dose subsequently used in phase III
- 2: Insufficient Follow up

Figure S1. PRISMA Flow Diagram – Study Identification, Selection and Exclusions.

*Monthly automated alerts from 01/12/13 to 01/06/14 consisting of updates to the search strategy identified an additional 429 articles in Embase, Medline and CENTRAL that have been included in flow diagram above. Two eligible studies for inclusion of the total 19 identified were obtained through these updates.
Figure S2. Forest Plots for risk of Stroke or Systemic Embolism in AF in Elderly (left) and Total Population (right).

*Event numbers for Engage-AF-Timi 48 in elderly have been estimated from published confidence intervals.
Figure S2. (contd) Forest Plots for risk of Stroke or Systemic Embolism in AF in Elderly (left) and Total Population (right).

*Event numbers for Engage-AF-Timi 48 in elderly have been estimated from published confidence intervals.
Figure S3. Forest Plots for risk of Recurrent Venous Thromboembolism in VTE in Elderly (left) and Total Population (right).
Figure S4. Forest Plots for risk of Major Bleeding in Elderly (left) and Total Population (right).

*Event numbers for Engage-AF-Timi-48 and J-Rocket AF in the elderly have been estimated from published confidence intervals.
Figure S4. (contd) Forest Plots for risk of Major Bleeding in Total Population (right).

*Event numbers for Engage-AF-Timi-48 and J-Rocket AF in the elderly have been estimated from published confidence intervals.
Figure S5. Forest Plots for risk of Gastrointestinal Bleeding in Elderly (left) and Total Population (right).
Figure S5. (contd) Forest Plots for risk of Gastrointestinal Bleeding in Total Population (right).
Figure S6. Forest Plots for risk of Intracranial Bleeding in Elderly (left) and Total Population (right).
Figure S6. (contd) Forest Plots for risk of Intracranial Bleeding in Total Population (right).
Figure S7. Forest Plots for risk of Clinically Relevant Bleeding in Elderly (left) and Total Population (right) - Random Effects Model
### Figure S7. (contd) Forest Plots for risk of Clinically Relevant Bleeding in Total Population (right)- Random Effects Model

#### 2.6.5 Edoxaban 60mg vs VKA

<table>
<thead>
<tr>
<th>Study</th>
<th>200 mg</th>
<th>300 mg</th>
<th>400 mg</th>
<th>500 mg</th>
<th>600 mg</th>
<th>750 mg</th>
<th>900 mg</th>
<th>1000 mg</th>
<th>Overall Event Rate</th>
<th>Event Rate CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Edox-J</td>
<td>92</td>
<td>125</td>
<td>125</td>
<td>75</td>
<td>75</td>
<td>75</td>
<td>75</td>
<td>75</td>
<td>75</td>
<td>250</td>
</tr>
<tr>
<td>Edox-P2A</td>
<td>8</td>
<td>80</td>
<td>5</td>
<td>5</td>
<td>5</td>
<td>5</td>
<td>5</td>
<td>5</td>
<td>5</td>
<td>75</td>
</tr>
<tr>
<td>ENGAGE-AF-TIMI 48</td>
<td>1520</td>
<td>7012</td>
<td>1761</td>
<td>7012</td>
<td>77.2%</td>
<td>0.00 (0.77, 0.90)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HAS-BLED-STE</td>
<td>384</td>
<td>4119</td>
<td>434</td>
<td>4172</td>
<td>21.7%</td>
<td>0.00 (0.89, 0.60)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### 2.6.6 Edoxaban 30mg vs VKA

<table>
<thead>
<tr>
<th>Study</th>
<th>200 mg</th>
<th>300 mg</th>
<th>400 mg</th>
<th>500 mg</th>
<th>600 mg</th>
<th>750 mg</th>
<th>900 mg</th>
<th>1000 mg</th>
<th>Overall Event Rate</th>
<th>Event Rate CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Edox-J</td>
<td>7</td>
<td>255</td>
<td>8</td>
<td>250</td>
<td>0.6%</td>
<td>0.90 (0.33, 2.60)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Edox-P2A</td>
<td>2</td>
<td>130</td>
<td>4</td>
<td>125</td>
<td>0.2%</td>
<td>0.47 (0.09, 2.60)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENGAGE-AF-TIMI 48</td>
<td>1161</td>
<td>7062</td>
<td>1761</td>
<td>7012</td>
<td>89.0%</td>
<td>0.50 (0.50, 0.64)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

For Edoxaban 60mg vs VKA:
- Total events: 1904
- Heterogeneity: Tau² = 0.00; CI: 0.00; df = 4 (P = 0.87), P = 0%
- Test for overall effect: Z = 5.38 (P = 0.00001)

For Edoxaban 30mg vs VKA:
- Total events: 1173
- Heterogeneity: Tau² = 0.00; CI: 0.00; df = 3 (P = 0.40), P = 0%
- Test for overall effect: Z = 12.41 (P = 0.00001)
Figure S8. Forest Plots for risk of Fatal Bleeding in Elderly (left) and Total Population (right).
Figure S8. (contd) Forest Plots for risk of Fatal Bleeding in Elderly (left) and Total Population (right).
Figure S9. Forest Plots for risk of All Cause Death in Atrial Fibrillation in Elderly (left) and Total Population (right).

*Event numbers for Rocket-AF in elderly have been estimated from published confidence intervals.
Figure S10. Forest Plots for risk of All Cause Death in Venous thromboembolism in Total Population (right).

*No results available for the elderly for this outcome
Figure S11. Forest Plots for risk of Stroke or Systemic Embolism in AF in Elderly (left) and <75 Population (right).

*Event numbers for Engage-AF-Timi 48 in elderly have been estimated from published confidence intervals.
Figure S12. Forest Plots for risk of Venous Thromboembolism in VTE in Elderly (left) and <75 Population (right).
**Figure S13. Forest Plots for risk of Major Bleeding in Elderly (left) and <75 Population (right).**

*Event numbers for Engage-AF-Timi-48 and J-Rocket AF in the elderly have been estimated from published confidence intervals.*
Figure S14. Forest Plots for risk of Gastrointestinal Bleeding in Elderly (left) and <75 Population (right).
Figure S15. Forest Plots for risk of Intracranial Bleeding in Elderly (left) and <75 Population (right).
Figure S16. Forest Plots for risk of Clinically Relevant Bleeding in Elderly (left) and <75 Population (right) - Random Effects Model.
Figure S17. Forest Plots for risk of Fatal Bleeding in Elderly (left) and <75 Population (right).
Figure S18. Forest Plots for risk of All Cause Death in AF in Elderly (left) and <75 Population (right).

*Event numbers for Rocket-AF in elderly have been estimated from published confidence intervals.
Figure S19. Funnel Plots for Stroke or Systemic Embolism in AF in Elderly (left) and Total population (right).
Figure S20. Funnel Plots for risk of Recurrent Venous Thromboembolism in VTE in Elderly (left) and Total population (right).
Supplemental References


